Home | Welcome to Contract Pharma   
Last Updated Friday, October 31 2014
Print RSS Feed

Search Results for 'Financial Report: AstraZeneca'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published August 8, 2014
Integration of BMS assets offsets losses Read More »
By Gil Roth
Published February 6, 2014
Generics drive sales down, more layoffs planned Read More »
Published October 31, 2013
Revenues, earnings fall off patent cliff Read More »
Published August 1, 2013
Generic erosion impacts results Read More »
Published April 25, 2013
Seroquel IR loss pummels revenues Read More »
Published January 31, 2013
Loss of exclusivity on multiple brands pummels results Read More »
Published July 26, 2012
Loss of exclusivity for key brands wallops results Read More »
Published July 19, 2012
Loss of exclusivity for key brands wallops results Read More »
Published February 2, 2012
Loss of nearly $2 billion in 2011 from generic competition, 7,300 more layoffs to come Read More »
Published April 23, 2007
AstraZeneca 1Q Revenues: $7 billion (+13%) 1Q Earnings: $1.6 billion (+10%) Comments: Growth in the quarter was driven by combined sales of five key products: Nexium, Seroquel, Crestor, Arimidex and Symbicort, up 17% to $3.6 billion. R&am… Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On